Arrowhead Pharmaceuticals Inc

Financials

Mittelzufluss aus laufender Geschäftstätigkeit -95.39 M171.22 M-136.13 M-153.89 M-462.85 M179.55 M 339.31 M Mittelzufluss aus Investitionstätigkeit -240.78 M-141.68 M-5.42 M-96.16 M-420.07 M-129.29 M -229.95 M Zahlungsströme aus der Finanzierungstätigkeit 257.95 M11.3 M65.19 M253.05 M870.52 M74.01 M 38.62 M Freier Cashflow -107.34 M147.66 M-188.91 M-330.63 M-604.32 M156.89 M 322.01 M

Arrowhead Pharmaceuticals, Inc. is a publicly traded biopharmaceutical company based in Pasadena, California. Arrowhead's products in development act through RNA interference mechanisms of action. The company focuses on treatments for hepatitis B, liver disease associated with alpha 1-antitrypsin deficiency and cardiovascular disease.

ARWR

Financials

Arrowhead Pharmaceuticals Inc

Nachrichten

TD Cowen bestätigt Kaufempfehlung für Arrowhead Pharma

BofA senkt Kursziel für Arrowhead Pharma wegen Adipositas-Aussichten

Wave Life Sciences Crashes 55% As 'Body Composition' Fat-Loss Drug Underwhelms

Arrowhead Pharmaceuticals: Transition Phase With Moderate Upside Ahead (NASDAQ:ARWR)

Wolfe Research bestätigt Ionis-Rating nach strategischer Preissenkung

Sarepta Plans FDA Filings Seeking Full Approval for Two DMD Therapies

SRPT Stock Up as Enrollment Begins in DMD Gene Therapy Safety Study

Arrowhead Pharmaceuticals auf der Leerink-Konferenz: Einblicke in die Pipeline-Strategie

Arrowhead Pharmaceuticals at Leerink Conference: Strategic Pipeline Insights

Arrowhead Pharmaceuticals at TD Cowen Conference: Strategic Insights in Cardiometabolic Focus

Sarepta Q4 Loss Wider Than Expected, Sales Beat Estimates

GSK Strikes $1 Billion China RNA Deal